HRV Pharma has launched RIKO™, an innovative AI-native pharmaceutical operating system designed to enhance decision-making across the pharmaceutical value chain.
RIKO™ leverages seven years of HRV Pharma's operational experience and institutional knowledge, differentiating itself from traditional AI by utilizing real-world data rather than solely public information. This self-learning system employs ten federated reasoning models that continuously adapt, enabling it to predict risks and identify opportunities with remarkable speed and accuracy. For instance, it boasts a 94% accuracy rate in detecting nitrosamine-related risks early in the assessment process, significantly expediting supplier qualification cycles by 85%.
Beyond mere automation, RIKO™ aims to enhance judgment and operational intelligence within the pharmaceutical industry. It evaluates various factors such as chemistry risk and supplier reliability, ensuring that potential issues are addressed proactively rather than reactively. This shift represents a fundamental change in how pharmaceutical companies approach operational risks, moving from a focus on manufacturing capacity to the importance of accumulated knowledge.
As the industry increasingly embraces digital transformation, HRV Pharma's RIKO™ sets a new standard by prioritizing high-quality decision-making before risks materialize, positioning itself as a leader in operational excellence and compliance within the pharmaceutical landscape.